Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/39369
Title: | Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors | Authors: | Konnova, Angelina De Winter, Fien H. R. Gupta, Akshita Verbruggen, Lise Hotterbeekx, An Berkell, Matilda Teuwen, Laure-Anne Vanhoutte, Greetje Peeters, Bart Raats, Silke Van der Massen, Isolde De Keersmaecker, Sven Debie, Yana Huizing, Manon Pannus, Pieter NEVEN, Kristof Arien, Kevin K. Martens, Geert A. Van den Bulcke, Marc Roelant, Ella Desombere, Isabelle Anguille, Sebastien Berneman, Zwi Goossens , Maria E. Goossens, Herman Malhotra-Kumar, Surbhi Tacconelli, Evelina Vandamme, Timon Peeters , Marc van Dam, Peter Kumar-Singh, Samir |
Issue Date: | 2022 | Publisher: | FRONTIERS MEDIA SA | Source: | Frontiers in Immunology, 13 (Art N° 1062136) | Abstract: | BackgroundPatients with cancer, especially hematological cancer, are at increased risk for breakthrough COVID-19 infection. So far, a predictive biomarker that can assess compromised vaccine-induced anti-SARS-CoV-2 immunity in cancer patients has not been proposed. MethodsWe employed machine learning approaches to identify a biomarker signature based on blood cytokines, chemokines, and immune- and non-immune-related growth factors linked to vaccine immunogenicity in 199 cancer patients receiving the BNT162b2 vaccine. ResultsC-reactive protein (general marker of inflammation), interleukin (IL)-15 (a pro-inflammatory cytokine), IL-18 (interferon-gamma inducing factor), and placental growth factor (an angiogenic cytokine) correctly classified patients with a diminished vaccine response assessed at day 49 with >80% accuracy. Amongst these, CRP showed the highest predictive value for poor response to vaccine administration. Importantly, this unique signature of vaccine response was present at different studied timepoints both before and after vaccination and was not majorly affected by different anti-cancer treatments. ConclusionWe propose a blood-based signature of cytokines and growth factors that can be employed in identifying cancer patients at persistent high risk of COVID-19 despite vaccination with BNT162b2. Our data also suggest that such a signature may reflect the inherent immunological constitution of some cancer patients who are refractive to immunotherapy. | Notes: | Kumar-Singh, S (corresponding author), Univ Antwerp, Fac Med & Hlth Sci, Lab Cell Biol & Histol, Mol Pathol Grp, Antwerp, Belgium.; Kumar-Singh, S (corresponding author), Univ Antwerp, Vaccine & Infect Dis Inst, Lab Med Microbiol, Antwerp, Belgium. samir.kumarsingh@uantwerpen.be |
Keywords: | COVID-19 vaccine;BNT162b2;SARS-CoV-2;solid cancers;haematological malignancies;cytokines;chemokines;growth factors | Document URI: | http://hdl.handle.net/1942/39369 | ISSN: | 1664-3224 | e-ISSN: | 1664-3224 | DOI: | 10.3389/fimmu.2022.1062136 | ISI #: | 000907564600001 | Rights: | 2022 Konnova, De Winter, Gupta, Verbruggen, Hotterbeekx, Berkell, Teuwen, Vanhoutte, Peeters, Raats, Massen, De Keersmaecker, Debie, Huizing, Pannus, Neven, Ariën, Martens, Bulcke, Roelant, Desombere, Anguille, Berneman, Goossens, Goossens, Malhotra-Kumar, Tacconelli, Vandamme, Peeters, van Dam and Kumar-Singh. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors.pdf | Published version | 2.51 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.